Page last updated: 2024-11-07

estrone and Premenstrual Dysphoric Disorder

estrone has been researched along with Premenstrual Dysphoric Disorder in 1 studies

Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.

Premenstrual Dysphoric Disorder: A condition in which a woman suffers from severe depression, irritability, and tension before MENSTRUATION. Premenstrual dysphoric disorder (PMDD) may involve a wide range of physical or emotional symptoms, which are more severe and debilitating than those seen with premenstrual syndrome (PMS), and which include at least one mood-related symptom. Symptoms usually stop when, or shortly after, menstruation begins.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nguyen, TV1
Reuter, JM1
Gaikwad, NW1
Rotroff, DM1
Kucera, HR1
Motsinger-Reif, A1
Smith, CP1
Nieman, LK1
Rubinow, DR1
Kaddurah-Daouk, R1
Schmidt, PJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement[NCT00001322]Phase 1/Phase 2100 participants (Actual)Interventional1994-06-09Completed
The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)[NCT00001259]Phase 160 participants (Actual)Interventional1992-08-11Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Beck Depression Inventory Score

"The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.~Each participant completed the BDI every 2 weeks during each of the study phases (i.e., GnRH agonist alone, estradiol and progesterone) throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone (phase 1), during the 4-week long estradiol phase (phase 2: weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (phase 2: weeks 2 and 4 of progesterone)." (NCT00001322)
Timeframe: Phase 1: Weeks 6 and 8 or 10 and 12; Phase 2: Weeks 2 and 4 of estradiol or progesterone

InterventionUnits on a scale (Mean)
Phase 1 - Lupron1.4
Phase 2 - Estradiol1
Phase 2 - Progesterone1.1

Mean Beck Depression Inventory Score

"The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.~Each participant completed the BDI every 2 weeks during each of the study phases throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone; weeks 6 and 8 of placebo alone; during the 4-week long estradiol phase (weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (weeks 2 and 4 of progesterone)." (NCT00001259)
Timeframe: Placebo: Weeks 6 and 8 of Placebo; Lupron only: Weeks 6 and 8 or 10 and 12; Estradiol or progesterone: Weeks 2 and 4

Interventionscore on a scale (Mean)
Placebo2.6
GnRH Agonist Injections (Lupron-L Only)3.0
Estradiol5.3
Progesterone3.6

Trials

1 trial available for estrone and Premenstrual Dysphoric Disorder

ArticleYear
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
    Translational psychiatry, 2017, 08-08, Volume: 7, Issue:8

    Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met

2017
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
    Translational psychiatry, 2017, 08-08, Volume: 7, Issue:8

    Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met

2017
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
    Translational psychiatry, 2017, 08-08, Volume: 7, Issue:8

    Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met

2017
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.
    Translational psychiatry, 2017, 08-08, Volume: 7, Issue:8

    Topics: Adult; Cross-Over Studies; Desoxycorticosterone; Estradiol; Estrone; Female; Humans; Leuprolide; Met

2017